Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

ACARIZAX - Health Canada Drug Approval Details

Approvals/Health Canada/ACARIZAX

Authorized

STANDARD

ACARIZAX

ALK-ABELLO A/S🇨🇦 Health Canada

Approval Date: Jul 4, 2025
Approval ID: dc5eee488380a7b2
Company: ALK-ABELLO A/S
Type: Standard

Approval Details

Approval Id: dc5eee488380a7b2
Drug Approval Canada Name: ACARIZAX
Product Name: ACARIZAX
Status: Marketed
Status Date: 2017-11-06
Original Market Date: 2017-11-06
Din: 02463644
Drug Class: Human
Dosage Form: Tablet
Route Of Administration: Sublingual
Schedule: Schedule D , Prescription
Ahfs: 92:05.00*
Atc Original: V01AA03 HOUSE DUST MITES
Atc Name: v 01 aa 03
Aig Number: 0223339003
Company Name: ALK-ABELLO A/S
Company Address: Boege Alle 6-8, Hoersholm, --, Denmark, 2970

Active Ingredients

DERMATOPHAGOIDES FARINAE

6 UNIT

DERMATOPHAGOIDES PTERONYSSINUS

6 UNIT

Authorized

Quick Info

Agency

Health Canada

Country

🇨🇦

Approval Date

Jul 4, 2025

Approval ID

dc5eee488380a7b2

Type

Standard

Back to Health Canada Approvals